Opexa Therapeutics plans to price public offering of its common stock

Aegis Capital helps fund Abili-T clinical study, corporate purposes

By Devika Patel

Knoxville, Tenn., Dec. 17 - Opexa Therapeutics, Inc. will conduct a public offering of common stock with a 45-day greenshoe, according to a preliminary prospectus supplement filed Tuesday with the Securities and Exchange Commission.

Aegis Capital Corp. is the bookrunning manager.

Proceeds will be used for general corporate purposes, including working capital, research and development, business development and operational purposes, and for the Abili-T clinical study.

The Woodlands, Texas-based Opexa develops and commercializes cell therapies to treat autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.